This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis
1 Primary · 1 Secondary · Reporting Duration: from Baseline to Week 12
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: VTAMA® (tapinarof) Cream 1% · No Placebo Group · Phase 4
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Indiana | 100.0% |
Met criteria | 100.0% |
3+ | 100.0% |